Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/01/2005WO2005079789A1 Combinatorial therapy with an acetylcholinesterase inhibitor and (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate
09/01/2005WO2005079788A1 Amino alcohol compound
09/01/2005WO2005079787A1 Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites
09/01/2005WO2005079786A1 Use of a compound modifying an interleukin 5, interleukin 6 and/or interleukin 10 secretion for preparing a pharmaceutical composition for rosacea treatment
09/01/2005WO2005079785A1 Remedies for hyperuricemia and/or gout
09/01/2005WO2005079784A1 Use of cholinesterase inhibitors for treating vascular depression
09/01/2005WO2005079783A1 Medicine capable of inhibiting activation of transcription factor klf5
09/01/2005WO2005079782A1 N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction
09/01/2005WO2005079781A1 Therapeutic and/or prophylactic method
09/01/2005WO2005079780A1 Amidine derivatives for treating amyloidosis
09/01/2005WO2005079779A1 THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
09/01/2005WO2005079778A2 Medicaments for treating barrett’s oesophagus
09/01/2005WO2005079777A1 Solid formulations of ospemifene
09/01/2005WO2005079776A1 Method for treatment or prevention of osteoporosis in individuals with high bone turnover
09/01/2005WO2005079775A1 Method and preparation for reducing irritation and/or inflammatory reaction in human skin
09/01/2005WO2005079774A2 Management of ophthalmologic disorders, including macular degeneration
09/01/2005WO2005079773A2 Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
09/01/2005WO2005079772A2 Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
09/01/2005WO2005079771A1 Methods to relief pain
09/01/2005WO2005079770A2 Use of a compound modulating at least one receiver selected in a group comprising an interleukin 8 type b receptor and pacap-1 receptor for preparing a pharmaceutical composition for rosacea treatment
09/01/2005WO2005079769A2 Piperazine derivatives for the treatment of endometriosis
09/01/2005WO2005079768A2 Amoxicillin instant granulate
09/01/2005WO2005079767A2 Means for modulation of the effects of opioid-like substances
09/01/2005WO2005079766A2 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
09/01/2005WO2005079765A1 Compositions for the treatment of nail and skin disorders
09/01/2005WO2005079764A1 Compositions and methods for timed release of water-soluble nutritional supplements
09/01/2005WO2005079763A2 Compression-coated tablets and manufacture thereof
09/01/2005WO2005079762A1 Multilayer tablet
09/01/2005WO2005079759A2 Pharmaceutical composition for oral application and method for preparing thereof
09/01/2005WO2005079758A1 A microemulsion preparation of high concentration propofol for anesthetic uses
09/01/2005WO2005079756A2 Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
09/01/2005WO2005079753A2 Extended release pharmaceutical compositions of divalproex sodium
09/01/2005WO2005079752A2 Controlled release pharmaceutical compositions with improved bioavailability
09/01/2005WO2005079749A2 Chitosan containing solution
09/01/2005WO2005079747A1 Pharmaceutical preparation for the oral cavity
09/01/2005WO2005079736A1 Composition for treating a dermatological inflammatory response and method of preparation thereof
09/01/2005WO2005079703A1 Biocompatible polymeric delivery systems for sustained release of quinazolinones
09/01/2005WO2005079603A1 Dietary fiber composition
09/01/2005WO2005079601A1 Novel dietary supplements or foodstuff based on unsaturated fatty acids and uses thereof
09/01/2005WO2005079574A1 Bicyclic melanocorin-specific compounds
09/01/2005WO2005079541A2 Terephthalamide peptidomimetic compounds and methods
09/01/2005WO2005079519A2 Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
09/01/2005WO2005079497A2 Substituted fused bicyclic amines as modulators of chemokine receptor activity
09/01/2005WO2005079496A2 Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
09/01/2005WO2005079471A2 Cytotoxin compound and method of isolation
09/01/2005WO2005079464A2 Vitamin d receptor antagonists and their use in treating asthma
09/01/2005WO2005079398A2 Drug conjugates
09/01/2005WO2005079384A2 Expandable gastric retention device
09/01/2005WO2005079367A2 Schizochytrium fatty acid synthase (fas) and products and methods related thereto
09/01/2005WO2005079344A2 Nicotine receptor agonists in stem cell and progenitor cell recruitment
09/01/2005WO2005079319A2 C10 cyclopentyl ester substituted taxanes
09/01/2005WO2005079317A2 Prostate hypertrophy treatment composition and method
09/01/2005WO2005079284A2 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
09/01/2005WO2005079272A2 Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
09/01/2005WO2005079270A2 2-substituted and 4-substituted aryl nitrone compouds
09/01/2005WO2005079267A2 Methods for protein production
09/01/2005WO2005079192A2 Novel treatment
09/01/2005WO2005079170A2 Polypeptide participating in pyridoxine biosynthesis, a polynucleotide coding the polypeptide and those uses
09/01/2005WO2005079164A2 5α-REDUCTASE INHIBITORS
09/01/2005WO2005070133A3 2,6-disubstituted piperidines as modulators of chemokine receptor activity
09/01/2005WO2005067388A3 Perturbed membrane-binding compounds and methods of using the same
09/01/2005WO2005066167A3 3-quinuclidinyl heteroatom bridged biaryl derivatives
09/01/2005WO2005066166A3 3-quinuclidinyl amino-substituted biaryl derivatives
09/01/2005WO2005066163A3 Thiophene derivatives as chk 1 inihibitors
09/01/2005WO2005065682A3 Rabeprazole containing formulation
09/01/2005WO2005065668A3 Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
09/01/2005WO2005065639A3 Novel pharmaceutical compositions
09/01/2005WO2005065435A3 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
09/01/2005WO2005063744A3 IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
09/01/2005WO2005063665B1 Propofol analogs, process for their preparation, and methods of use
09/01/2005WO2005058966A3 Use of ligands of specific antigen for the diagnosis and treatment of solid tumours and bone-related cancerous diseases
09/01/2005WO2005058480A3 Particle and particle manufacturing method and apparatus
09/01/2005WO2005053609A3 Methods of nad+-dependent deacetylase inhibitors
09/01/2005WO2005051401A3 Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
09/01/2005WO2005049080B1 Vaccine composition admixed with an alkylphosphatidylcholine
09/01/2005WO2005046586A8 M3 muscarinic acetylcholine receptor antagonists
09/01/2005WO2005042533A3 2-cyanopyrrolidinecarboxamides as dipeptidyl peptidase-iv inhibitors
09/01/2005WO2005042060A3 Method and composition comprising pyruvate, inosine, adenine, phosphate and an aziridino compound for treating a biological sample
09/01/2005WO2005041878A3 Compositions and methods for increasing hdl and hdl-2b levels
09/01/2005WO2005041853B1 Antibacterial and/or antiprotozoal nitroimidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines.
09/01/2005WO2005039482A3 Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof
09/01/2005WO2005037995A3 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
09/01/2005WO2005037271A3 Large conductance calcium-activated k channel opener
09/01/2005WO2005037200A8 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
09/01/2005WO2005034880A3 Thiophene and benzothiophene hydroxamic acid derivatives
09/01/2005WO2005034839A3 Porifera-based therapeutic compositions for treating and preventing skin diseases
09/01/2005WO2005030137A3 Improving biomechanical performance of irradiated biological material
09/01/2005WO2005026253A3 Labile linkage for compound delivery to a cell
09/01/2005WO2005023178A3 Acridone derivatives as anti-herpesvirus agents
09/01/2005WO2005021523A8 Piperazine substituted compounds used as calcium channel blockers
09/01/2005WO2005018627A8 Alpha-aminoamide derivatives useful as anti-inflammatory agents
09/01/2005WO2005013950A3 Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
09/01/2005WO2005011593A3 Improved binding of pantoprazole to the acid pump
09/01/2005WO2005003374A3 SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES
09/01/2005WO2005002519A3 Amphiphilic pyridinium compounds, method of making and use thereof
09/01/2005WO2005002508B1 Macromolecular platinum chelates
09/01/2005WO2005002506A3 Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites
09/01/2005WO2005000219A3 Composition for blocking hiv binding to dendritic cells and methods of use thereof
09/01/2005WO2004103394B1 Method and compositions for nerve regeneration
09/01/2005WO2004098561A3 Particulate materials
1 ... 4556 4557 4558 4559 4560 4561 4562 4563 4564 4565 4566 4567 4568 4569 4570 4571 4572 4573 4574 4575 4576 ... 7860